Cancer Archives

News and Trends 6 Jan 2023

BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies

BioNTech SE has signed a memorandum of understanding (MoU) with the Government of the United Kingdom. The deal is set to benefit patients by speeding up clinical trials for personalized mRNA immunotherapies. The aim is to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either through clinical trials or […]

January 6, 2023 - 4 minutesmins - By Jim Cornall

In Depth 5 Jan 2023

Navignostics maps tumor proteomes to improve precision oncology

New cancer drugs are entering the market every year, but it’s hard to know which patients they benefit the most. The Swiss firm Navignostics is making spatial maps of the tumor’s proteome to identify the right treatment for the patient and boost precision oncology approaches. A wide range of technologies is being deployed in the […]

January 5, 2023 - 4 minutesmins - By Jonathan Smith

News and Trends 5 Jan 2023

Cancer Research UK and Turbine to partner on program

Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK, has announced that it is partnering with Turbine AI, a tech-enabled biotech leveraging its proprietary Simulated Cell platform to solve complex diseases. The partnership will utilize Turbine AI’s platform to identify target patient populations […]

January 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Jan 2023

Hummingbird Bioscience and Synaffix to develop ADC program

Synaffix B.V. and Hummingbird Bioscience have entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation antibody drug conjugate (ADC) program using Synaffix technology. Synaffix is a biotechnology company focused on commercializing its clinical-stage platform technology for the development of ADCs. Hummingbird Bioscience is a data-driven precision biotherapeutics company using […]

January 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Jan 2023

Actimed Therapeutics raises £10M for cancer cachexia treatment

Actimed Therapeutics Ltd has completed its second and final £5 million ($6 million) tranche of seed financing. The round was closed with an investment by Indian pharmaceutical company, Mankind Pharma, marking Mankind’s first overseas investment of this type. Actimed Therapeutics is a U.K. based clinical stage specialty pharmaceutical company focused on bringing innovation to the […]

January 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Janssen looks for talquetamab marketing approval

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for approval of talquetamab for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody targeting both GPRC5D, a novel drug […]

January 3, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Legend Biotech new drug application approved in China

Legend Biotech Corporation has announced that China’s National Medical Products Administration (NMPA) has formally accepted its new drug application (NDA) for ciltacabtagene autoleucel (cilta-cel). This submission is based on data from the confirmatory phase 2 clinical study CARTIFAN-1, conducted in China, which evaluated the efficacy and safety of cilta-cel in adult patients with relapsed or […]

January 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Sensorion announces first patient enrolled in cisplatin-induced ototoxicity trial

Sensorion has announced that the first patient has been enrolled in its phase 2a proof of concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, […]

January 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Blacksmith Medicines merging with Forge Therapeutics

Blacksmith Medicines, Inc., and Forge Therapeutics have signed a definitive merger agreement. This will create a biopharma company dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes. The initial focus will be on oncology and infection. “We are excited to unveil the merger of Blacksmith and Forge, which we believe […]

January 3, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 1 Jan 2023

Watch: Roquefort Therapeutics at BioFIT

Roquefort Therapeutics is a biotech company developing first-in-class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth […]

January 1, 2023 - 1 minutemin - By Jim Cornall

News and Trends 23 Dec 2022

Affibody signs €20 million loan agreement

Affibody Medical AB has received a €20 million ($21.2 million) venture debt loan facility from the European Investment Bank, EIB, backed by the InvestEU program. The investment will support Affibody’s research and development activities in Europe of the next-generation biopharmaceuticals targeting unmet medical needs in the immunology and oncology fields. “We are very pleased and […]

December 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Dec 2022

Mersana Therapeutics and Merck to develop novel ADCs

Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug conjugates (ADCs) directed against up to two targets. Immunosynthen, Mersana Therapeutics’ proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both […]

December 23, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies

Navignostics maps tumor proteomes to improve precision oncology

Cancer Research UK and Turbine to partner on program

Hummingbird Bioscience and Synaffix to develop ADC program

Actimed Therapeutics raises £10M for cancer cachexia treatment

Janssen looks for talquetamab marketing approval

Legend Biotech new drug application approved in China

Sensorion announces first patient enrolled in cisplatin-induced ototoxicity trial

Blacksmith Medicines merging with Forge Therapeutics

Watch: Roquefort Therapeutics at BioFIT

Affibody signs €20 million loan agreement

Mersana Therapeutics and Merck to develop novel ADCs

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!